The Methylmalonic Acidemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Methylmalonic Acidemia: An Overview
Methylmalonic acidemia (MMA) is an inherited disorder and a type of “inborn error of metabolism.” In this condition, the body is unable to process or break certain proteins and fats (lipids) properly from the consumed food. The disease usually appears in early infancy, varying from mild to life-threatening. Mutations cause the disorder in the MMUT, MMAA, MMAB, MMADHC, and MCEE genes.
MMA is biochemically characterized by the gathering of methylmalonic acid in all body fluids and tissues. If a metabolic crisis is not treated, the patient can develop breathing problems, seizures, stroke, coma, sometimes death.
Methylmalonic Acidemia Market Key Facts
-
According to the research study published by An et al. titled, “Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia,” stated that Isolated methylmalonic acidemia/aciduria (MMA) is a devastating metabolic disorder with poor outcomes despite current medical treatments. The disease affects 1 in 50,000–100,000 individuals.
-
“Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia” by Baumgartner et al. specified that Methylmalonic acidemia (MMA) is the inborn errors of metabolism considered by the accumulation of methylmalonic acid due to deficiency of methylmalonyl-CoA mutase (MUT). MMA has an estimated incidence of approximately 1:50,000.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Methylmalonic Acidemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Methylmalonic Acidemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Methylmalonic Acidemia Epidemiology
The epidemiology section covers insights about the historical and current Methylmalonic Acidemia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Methylmalonic Acidemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Methylmalonic Acidemia market or expected to get launched in the market during the study period. The analysis covers Methylmalonic Acidemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Methylmalonic Acidemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market
Methylmalonic Acidemia Therapeutics Analysis
The dynamics of the Methylmalonic Acidemia (MMA) market is anticipated to change in the coming years owing to the launch of the emerging therapies.
Methylmalonic Acidemia (MMA) Companies:
-
ModernaTX
-
LogicBio Therapeutics
-
HemoShear Therapeutics
And many others.
Methylmalonic Acidemia (MMA) Therapies covered in the report include:
-
mRNA-3704
-
LB-001
-
HST5040
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market
Table of Content
1. Key Insights
2. Executive Summary
3. Methylmalonic Acidemia Competitive Intelligence Analysis
4. Methylmalonic Acidemia Market Overview at a Glance
5. Methylmalonic Acidemia Disease Background and Overview
6. Methylmalonic Acidemia Patient Journey
7. Methylmalonic Acidemia Epidemiology and Patient Population
8. Methylmalonic Acidemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Methylmalonic Acidemia Unmet Needs
10. Key Endpoints of Methylmalonic Acidemia Treatment
11. Methylmalonic Acidemia Marketed Products
12. Methylmalonic Acidemia Emerging Therapies
13. Methylmalonic Acidemia Seven Major Market Analysis
14. Attribute Analysis
15. Methylmalonic Acidemia Market Outlook (7 major markets)
16. Methylmalonic Acidemia Access and Reimbursement Overview
17. KOL Views on the Methylmalonic Acidemia Market.
18. Methylmalonic Acidemia Market Drivers
19. Methylmalonic Acidemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market
Other Latest Healthcare Reports By DelveInsight
DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of the key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/